METHOD FOR DETERMINING ACTIVITY OF MANNAN-BINDING LECTIN-ASSOCIATED SERINE PROTEASES IN A FIBRINOGEN COAGULATION TEST Russian patent published in 2020 - IPC G01N33/50 C12Q1/37 

FIELD: clinical immunology; haemostasiology.

SUBSTANCE: invention relates to determining the activity of mannan-binding lectin-associated serine proteases-1 and 2 (MASP-1,2) in a fibrinogen coagulation test. A method for determining activity of mannan-binding lectin-associated serine proteases-1 and 2 (MASP-1 and MASP-2) in a fibrinogen coagulation test, involving the use of EDTA plasma as a source of fibrinogen MASP-1 and MASP-2, and as the activator of the lectin pathway of the complement system used is yeast mannan, activation of MASP activation is started by adding 25 mcl of 10 % CaCl₂ diluted (1:31) solution to 25 mcl of the fused EDTA-blood plasma of healthy donors and 50 mcl of tris-imidazole buffer, pH 7.4, then degree of fibrinogen coagulation is determined as difference of change of turbidity of sample at 450 nm after 45 minute incubation at 37 °C, degree of coagulation is evaluated relative to sample, containing human thrombin in place of human blood plasma analyzed, maximum absorption of fibrin clot obtained with thrombin at 450 nm is taken as 100 % coagulation of fibrinogen, wherein coagulation to 25 % is considered low activity of MASP-1 and MASP-2 in fibrinogen coagulation test, from 26 % to 49 % as average activity of MASP-1 and MASP-2 and higher than 50 % as high activity of MASP-1 and MASP-2 in fibrinogen coagulation test.

EFFECT: invention provides extending the range of laboratory screening tests for diagnosing hypercoagulation and thrombosis threat caused by high functional activity of MASP-1,2 in fibrinogen coagulation test.

1 cl, 4 tbl, 2 ex